

## FACTSHEET H1 2025



~60  
development  
projects\*



> 390  
pharmaceutical  
ingredients\*



> 1,300  
marketing  
authorisations\*



3,518  
employees  
worldwide\*

\* Figures: Status 30 Jun 2025

## COMPANY PROFILE

**Dermapharm is a fast-growing manufacturer of branded pharmaceuticals and other healthcare products.** Founded in 1991, the company is based in Grünwald near Munich. In addition to its main site in Sandersdorf-Brehna near Leipzig, Dermapharm operates further production, development and sales sites primarily within Europe and in the USA. Dermapharm employs 3,518 people worldwide as of June 30, 2025.

## REASONS TO INVEST

- 01** Clear focus on **Europe** as a quality location
- 02** **High-growth pharmaceutical manufacturer** in selected, **profitable niche markets**
- 03** In-house **R&D competence**
- 04** Pipeline with **~60 ongoing development projects**
- 05** **Successful track record** in acquisitions
- 06** Expansion of **international presence**

KEY FIGURES (IFRS)<sup>1</sup>

		H1 2025	H1 2024	2023	2022	2021
Revenue	EUR million	574.5	578.5	1,135.4	1,024.8	942.9
Adjusted EBITDA	EUR million	148.0	153.0	310.2	359.8	351.1
Adjusted EBITDA-margin	%	25.8	26.4	27.3	35.1	37.2
Unadjusted EBITDA	EUR million	144.9	147.0	280.3	331.3	354.4
Unadjusted EBITDA-margin	%	25.2	25.4	24.7	32.3	37.6
Operating income	EUR million	104.3	102.9	182.9	243.7	298.5
Earnings before taxes	EUR million	82.2	90.7	106.0	216.3	293.0
Profit or (loss) for the period	EUR million	54.1	59.9	60.5	132.6	208.9
Earnings per share	EUR	1.01	1.13	1.16	2.49	3.89

## FINANCIAL CALENDAR 2025

Publication of Q3 Quarterly Report  
13 November 2025

Participation in the German Equity Forum  
24 November 2025

## DERMAPHARM SHARE IN COMPARISON



Source: Xetra closing prices

## FACTS ABOUT DERMAPHARM SHARE

Ticker symbol	DMP
Ticker Symbol Bloomberg	DMP:GR
Ticker Symbol Reuters	DMPG.DE
WKN	A2GS5D
ISIN	DE000A2GS5D8
Number of shares	53.84 Mio.
IPO	09 February 2018
Stock Exchange	Regulated Market (Prime Standard) of the Frankfurt Stock Exchange

## CONTACT

## Dermapharm Holding SE

Investor Relations & Corporate Communications  
Britta Hamberger  
Tel.: +49 (0)89 641 86 233, E-Mail: [ir@dermapharm.com](mailto:ir@dermapharm.com)

## NOTICE

*This publication contains various statements concerning the future development of the Dermapharm Group. These statements are based on both assumptions and estimates. Our assumptions involve risks and uncertainties that could cause actual results to differ materially from those anticipated. There are no plans to update the forward-looking statements. Throughout this publication, apparent differences may occur due to mathematical rounding during addition.*

# THE THREE SEGMENTS OF DERMAPHARM HOLDING SE (INTEGRATED BUSINESS MODEL)



## Branded pharmaceuticals

The segment comprises around 390 pharmaceutical active ingredients, resulting in over 1,300 national and international drug approvals. The range of medicinal products, medical devices and food supplements is specialised in selected therapeutic areas in which Dermapharm occupies a leading market position, particularly in Germany.


## Other healthcare products

In the "Other healthcare products" segment, Dermapharm mainly combines herbal extracts, nutritional supplements, herbal medicinal products and cosmetics as well as medical devices. In addition to the French company Arkopharma, the market leader for phytotherapeutic dietary supplements in France, the segment also includes the Spanish company Euromed S.A., a leading global manufacturer of plant extracts and herbal active ingredients for the pharmaceutical, nutraceutical, food, and cosmetics industries.

## Parallel import business

Dermapharm's business model also includes a "Parallel import business" segment, which is operated under the "axicorp" brand. Based on turnover, axicorp is the seventh-largest parallel importer in Germany in the first half of 2025.


## REVENUE BY SEGMENTS



## 2025 GUIDANCE:

Group Revenue **EUR 1,160 million to EUR 1,200 million**  
vs. previous year (EUR 1,180.8 million)


## ADJUSTED EBITDA BY SEGMENTS



## 2025 GUIDANCE:

Adjusted Group EBITDA **EUR 322 million to EUR 332 million**  
vs. previous year (EUR 315.6 million)

## ADJUSTED EBITDA MARGIN



Branded pharmaceuticals (since 2023, before Branded pharmaceuticals and other healthcare products)

Other healthcare products (since 2023, before Herbal extracts)

Parallel import business

Total